95 related articles for article (PubMed ID: 26026911)
1. Piperlongumine is a novel nuclear export inhibitor with potent anticancer activity.
Niu M; Xu X; Shen Y; Yao Y; Qiao J; Zhu F; Zeng L; Liu X; Xu K
Chem Biol Interact; 2015 Jul; 237():66-72. PubMed ID: 26026911
[TBL] [Abstract][Full Text] [Related]
2. CRM1 is a direct cellular target of the natural anti-cancer agent plumbagin.
Liu X; Niu M; Xu X; Cai W; Zeng L; Zhou X; Yu R; Xu K
J Pharmacol Sci; 2014; 124(4):486-93. PubMed ID: 24739265
[TBL] [Abstract][Full Text] [Related]
3. Piperlongumine selectively suppresses ABC-DLBCL through inhibition of NF-κB p65 subunit nuclear import.
Niu M; Shen Y; Xu X; Yao Y; Fu C; Yan Z; Wu Q; Cao J; Sang W; Zeng L; Li Z; Liu X; Xu K
Biochem Biophys Res Commun; 2015 Jul; 462(4):326-31. PubMed ID: 25979358
[TBL] [Abstract][Full Text] [Related]
4. A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export.
Daelemans D; Afonina E; Nilsson J; Werner G; Kjems J; De Clercq E; Pavlakis GN; Vandamme AM
Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14440-5. PubMed ID: 12374846
[TBL] [Abstract][Full Text] [Related]
5. Piperlongumine (piplartine) as a lead compound for anticancer agents - Synthesis and properties of analogues: A mini-review.
Piska K; Gunia-Krzyżak A; Koczurkiewicz P; Wójcik-Pszczoła K; Pękala E
Eur J Med Chem; 2018 Aug; 156():13-20. PubMed ID: 30006159
[TBL] [Abstract][Full Text] [Related]
6. Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells.
Jarvius M; Fryknäs M; D'Arcy P; Sun C; Rickardson L; Gullbo J; Haglund C; Nygren P; Linder S; Larsson R
Biochem Biophys Res Commun; 2013 Feb; 431(2):117-23. PubMed ID: 23318177
[TBL] [Abstract][Full Text] [Related]
7. Development and mechanism investigation of a new piperlongumine derivative as a potent anti-inflammatory agent.
Sun LD; Wang F; Dai F; Wang YH; Lin D; Zhou B
Biochem Pharmacol; 2015 Jun; 95(3):156-69. PubMed ID: 25850000
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological activity of piperlongumine derivatives as selective anticancer agents.
Wu Y; Min X; Zhuang C; Li J; Yu Z; Dong G; Yao J; Wang S; Liu Y; Wu S; Zhu S; Sheng C; Wei Y; Zhang H; Zhang W; Miao Z
Eur J Med Chem; 2014 Jul; 82():545-51. PubMed ID: 24937186
[TBL] [Abstract][Full Text] [Related]
9. Supraphysiological nuclear export signals bind CRM1 independently of RanGTP and arrest at Nup358.
Engelsma D; Bernad R; Calafat J; Fornerod M
EMBO J; 2004 Sep; 23(18):3643-52. PubMed ID: 15329671
[TBL] [Abstract][Full Text] [Related]
10. Identification of multiple nuclear export sequences in Fanconi anemia group A protein that contribute to CRM1-dependent nuclear export.
Ferrer M; Rodríguez JA; Spierings EA; de Winter JP; Giaccone G; Kruyt FA
Hum Mol Genet; 2005 May; 14(10):1271-81. PubMed ID: 15790592
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action.
Van Neck T; Pannecouque C; Vanstreels E; Stevens M; Dehaen W; Daelemans D
Bioorg Med Chem; 2008 Nov; 16(21):9487-97. PubMed ID: 18835718
[TBL] [Abstract][Full Text] [Related]
12. Horner-Wadsworth-Emmons approach to piperlongumine analogues with potent anti-cancer activity.
Han LC; Stanley PA; Wood PJ; Sharma P; Kuruppu AI; Bradshaw TD; Moses JE
Org Biomol Chem; 2016 Aug; 14(31):7585-93. PubMed ID: 27443386
[TBL] [Abstract][Full Text] [Related]
13. Piperlongumine and some of its analogs inhibit selectively the human immunoproteasome over the constitutive proteasome.
Bosc E; Nastri J; Lefort V; Valli M; Contiguiba F; Pioli R; Furlan M; Bolzani VDS; El Amri C; Reboud-Ravaux M
Biochem Biophys Res Commun; 2018 Feb; 496(3):961-966. PubMed ID: 29355526
[TBL] [Abstract][Full Text] [Related]
14. Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent.
Tripathi SK; Biswal BK
Pharmacol Res; 2020 Jun; 156():104772. PubMed ID: 32283222
[TBL] [Abstract][Full Text] [Related]
15. A novel transferable nuclear export signal mediates CRM1-independent nucleocytoplasmic shuttling of the human cytomegalovirus transactivator protein pUL69.
Lischka P; Rosorius O; Trommer E; Stamminger T
EMBO J; 2001 Dec; 20(24):7271-83. PubMed ID: 11743003
[TBL] [Abstract][Full Text] [Related]
16. Novel non-trimethoxylphenyl piperlongumine derivatives selectively kill cancer cells.
Zhang Y; Ma H; Wu Y; Wu Z; Yao Z; Zhang W; Zhuang C; Miao Z
Bioorg Med Chem Lett; 2017 Jun; 27(11):2308-2312. PubMed ID: 28434764
[TBL] [Abstract][Full Text] [Related]
17. Beta-catenin can bind directly to CRM1 independently of adenomatous polyposis coli, which affects its nuclear localization and LEF-1/beta-catenin-dependent gene expression.
Ki H; Oh M; Chung SW; Kim K
Cell Biol Int; 2008 Apr; 32(4):394-400. PubMed ID: 18262809
[TBL] [Abstract][Full Text] [Related]
18. CRM1 mediates nuclear export of HDAC7 independently of HDAC7 phosphorylation and association with 14-3-3s.
Gao C; Li X; Lam M; Liu Y; Chakraborty S; Kao HY
FEBS Lett; 2006 Sep; 580(21):5096-104. PubMed ID: 16956611
[TBL] [Abstract][Full Text] [Related]
19. Preformulation Studies on Piperlongumine.
Aodah A; Pavlik A; Karlage K; Myrdal PB
PLoS One; 2016; 11(3):e0151707. PubMed ID: 26982320
[TBL] [Abstract][Full Text] [Related]
20. CRM1 inhibitor S109 suppresses cell proliferation and induces cell cycle arrest in renal cancer cells.
Liu X; Chong Y; Liu H; Han Y; Niu M
Korean J Physiol Pharmacol; 2016 Mar; 20(2):161-8. PubMed ID: 26937212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
